Summa Equity completed the acquisition of Pierian, a clinical genomics technology and services provider, Seven Bridges, a biomedical data analysis company, and UgenTec, a molecular laboratory software provider. Financial terms were not disclosed. “Summa is driven by a mission to improve the world, through our impact-focused investments in era-defining issues. We believe that the combination of these three leading healthcare and life sciences companies will accelerate innovation and deliver change at remarkable scale, contributing to the Summa thesis and our dedication to the UN Sustainable Development Goals. Velsera’s creation meets UN SDG Goal 3, good health and well-being, by reducing the cost of development of new diagnostics, therapies and drugs, as well as increasing access for underserved populations, and driving global adoption of new bio-computational methods,” Hans Cobben, Summa Equity Thematic Partner.